A breast cancer second opinion in Germany brings specialist review of pathology, imaging, biomarker results, and treatment history together to reassess a diagnosis or proposed treatment plan. Rather than replacing an existing care team, this kind of review offers an additional, evidence-based assessment that can help determine whether a recommendation remains appropriate, particularly when a diagnosis is complex, a major surgical decision is pending, or the disease has recurred. In Germany, this review can be coordinated through breast centers certified by the German Cancer Society (DKG), where multidisciplinary tumor boards bring surgery, medical and radiation oncology, radiology, and pathology together to review a case. Published studies show that second opinions sometimes support the original plan and sometimes change it, so results cannot be predicted for any individual patient.

International Breast Cancer Care in Germany: Specialist Review and Treatment Decisions

A breast cancer diagnosis or treatment recommendation made abroad can feel definitive. Still, some cases benefit from a specialist second opinion, particularly when the diagnosis is complex or a major treatment decision is involved.

A specialist review in Germany brings together pathology, imaging, biomarker results, and treatment history to reassess the diagnosis and proposed treatment plan. This can help clarify whether the recommended approach is appropriate for the individual patient's cancer and clinical circumstances. A second opinion may be useful shortly after diagnosis, before a major surgical decision, when treatment recommendations are unclear, or when the cancer has recurred or progressed and the next step is less straightforward.

The purpose is not to replace the patient's existing care team. It is to provide an additional multidisciplinary assessment that can confirm, clarify, or reconsider the proposed approach based on the available clinical information and current evidence.

Reassessing Breast Cancer Diagnosis and Treatment Recommendations

A second opinion after a breast cancer diagnosis or treatment recommendation made abroad begins with a review of the pathology and imaging. Specialists assess the tumor type, grade, and histological features and compare them with the available breast imaging, such as mammography and ultrasound, to see whether the findings are consistent. MRI may also be reviewed or recommended when it is clinically indicated, for example to clarify the extent of disease or answer a specific diagnostic question.

Estrogen receptor (ER), progesterone receptor (PR), and HER2 status are reviewed because they can influence endocrine and HER2-directed treatment decisions. When pathology or biomarker findings are uncertain or discordant with the clinical and imaging findings, specialists may request additional pathology review, repeat biomarker testing, or other diagnostic investigations when clinically appropriate [1] [2].

When breast cancer has spread to other organs, whether at first diagnosis or after a recurrence, the ESMO metastatic guideline recommends a biopsy of a metastatic lesion, when feasible, to confirm the diagnosis and reassess ER, PR, and HER2 status. Receptor status can differ from the original tumor, and such differences can influence treatment choices [3].

Lymph-node findings and the overall extent of disease are considered alongside pathology and imaging because they contribute to staging and treatment planning. For patients who have already received surgery, systemic therapy, or radiation, the review also considers previous treatment and the disease's response, since this information can influence subsequent management [1].

A second opinion does not necessarily change the original diagnosis or treatment plan, and in many cases it supports the initial assessment and proposed management. Review is particularly useful when pathology, imaging, or other clinical findings are discordant, uncertain, or likely to affect a major treatment decision. Published studies report both agreement with the original findings and changes in diagnosis or management, depending on the patient population and type of review [4] [5].

A meaningful review depends on access to the underlying clinical material, not only written summaries. International patients may be asked to provide:

• Original pathology slides or tissue blocks
• Imaging studies themselves, such as mammography, ultrasound, or MRI, rather than reports alone
• Pathology and biomarker reports
• Records of previous surgery, systemic treatment, radiation, and treatment response

Patients should ask the receiving center in advance which records and imaging formats it requires, since the original material lets the team assess the evidence directly rather than rely solely on earlier reports.

Examples of findings reported in selected breast cancer second-opinion studies

The two studies below examined selected patients who sought specialist second opinions, including patients in Germany and at the Netherlands Cancer Institute. They used different populations and definitions for diagnostic or treatment changes, so their findings are not directly comparable and should not be interpreted as a prediction for any individual patient. Together, they illustrate that specialist review may confirm the original assessment or identify differences in diagnosis or treatment planning when further assessment is needed [4] [5].

Reviewing Breast Cancer Treatment and Surgical Decisions in Germany

A diagnosis review asks whether the pathology and imaging have been interpreted correctly, while a treatment review considers whether the recommended strategy is appropriate for the individual patient.

A specialist review may assess [1] [2]:

• Whether breast-conserving surgery or mastectomy is appropriate based on tumor characteristics, disease extent, and other clinical factors, and whether axillary surgery is indicated, including sentinel lymph node biopsy, axillary lymph node dissection, or omission of sentinel lymph node biopsy in selected patients.
• Whether immediate or delayed breast reconstruction should be considered alongside the planned cancer treatment.
• Whether systemic treatment should be given before surgery (neoadjuvant) or after surgery (adjuvant), based on tumor characteristics, biomarkers, and disease extent.

For previously treated patients, how recurrence or progression affects the next treatment decision.

A treatment review may support the existing recommendation or identify aspects that warrant further discussion. It is intended to provide an evidence-based assessment of the individual case and can be coordinated with the patient's existing treatment team.

Treatment Planning by Breast Cancer Situation

How a specialist review is approached differs by clinical situation.

• Newly diagnosed breast cancer: review usually focuses on confirming the diagnosis and assessing the proposed initial treatment strategy before major decisions are made.
• Early-stage breast cancer: review may consider the surgical approach, the indication for radiotherapy, and whether systemic treatment is appropriate, depending on the tumor characteristics and the patient's clinical situation.
• Locally advanced breast cancer: reassessment often considers neoadjuvant treatment sequencing and coordinated, multidisciplinary planning.
• Recurrent breast cancer: review focuses on how the current recurrence relates to previous treatment and which options remain appropriate.
• Metastatic breast cancer: reassessment considers the overall treatment strategy within a multidisciplinary approach, consistent with current ESMO guidance for this setting [3].
• Complex or uncommon cases: specialist review may help clarify the diagnosis, treatment sequence, or suitability of available options when the clinical situation is less straightforward.

Coordinated Breast Cancer Care Through a German Breast Center

Germany has an established certification framework for breast cancer centers, with defined structural, quality, and interdisciplinary requirements. The certification framework supports interdisciplinary cooperation among specialties such as breast surgery, medical and radiation oncology, radiology, and pathology. The German Cancer Society (DKG) and its certification body, OnkoZert, oversee these requirements [6] [7].

Depending on the clinical situation and the center's procedures, specialists may discuss imaging, pathology, biomarkers, treatment history, and other relevant findings in a multidisciplinary tumor board, which allows treatment options and sequencing to be considered together rather than in isolation [2] [3].

German studies have found higher fulfillment of selected guideline-based quality indicators in centers certified under Germany's breast-center certification framework, although observational research cannot establish that certification alone causes better outcomes [6][8].

Continuing Breast Cancer Care After Treatment in Germany

After treatment or a specialist review in Germany, patients can receive a summary of their findings, recommendations and care to share with their home-country medical team. Records may include:

• Treatment summary and specialist recommendations.
• Pathology reports, imaging and relevant test results.
• Surgery, medication or radiotherapy details.
• Updated biomarker results, if retested.

Follow-up may involve imaging, treatment-response monitoring and further consultations. Remote review of new results depends on the treating center and clinical requirements.

For international patients, Treatment in Germany (TIG)  can help coordinate medical record reviews and communication with German healthcare providers. Treatment costs vary according to the proposed plan, hospital and individual needs; an estimate can be provided after medical review. Further specialist assessment may be considered if the disease changes or a complex treatment decision arises.

References

1. S3-Leitlinie Mammakarzinom, Version 5.1 (Leitlinienprogramm Onkologie/AWMF, June 2026)

2. Loibl S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159–182. doi:10.1016/j.annonc.2023.11.016

3. de Azambuja E, Barrios CH, Bartsch R, et al; ESMO Guidelines Committee. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(9):1203–1219. doi:10.1016/j.annonc.2026.05.707

4. Cecon N, Hillen MA, Pfaff H, Dresen A, Groß SE. Why do newly diagnosed breast cancer patients seek a second opinion? Second opinion seeking and its association with the physician-patient relationship. Patient Educ Couns. 2019;102(5):998–1004. doi:10.1016/j.pec.2018.12.017

5. Heeg E, Civil YA, Hillen MA, Smorenburg CH, Woerdeman LAE, Groen EJ, Winter-Warnars HAO, Vrancken Peeters MTFD. Impact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis. Ann Surg Oncol. 2019;26(13):4355–4363. doi:10.1245/s10434-019-07907-6

6. Brucker SY, Bamberg M, Jonat W, Beckmann MW, Kämmerle A, Kreienberg R, Wallwiener D. Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care. BMC Cancer. 2009;9:228. doi:10.1186/1471-2407-9-228

7. OnkoZert. International Certification (on behalf of the German Cancer Society).

8. Schulz S, Lange C, Emrich K, Justenhoven C. Quality Indicators Show Higher Fulfilment in Centers Certified by the German Cancer Society. Gesundheitswesen. 2024;86(12):783–787.

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained